Enrui Kainuo Company completes over 200 million Yuan in Series A financing, accelerating innovative drug development and global expansion

Arterial Network learned that recently, Shenzhen Enrui Kairuono Biotechnology Co., Ltd. (hereinafter referred to as "Enrui Kairuono") has completed an A-round financing of over 200 million RMB. This round of financing was led bySDVC, Hengqin Venture Capital under Zhuhai Science and Technology Industry Group, Songhe CapitalCo-led,Tasly Capital, Nanshan Strategic Emerging Investment, Nanshan Venture Capital, Anhui Wanbang PharmaceuticalFollow-on Investment, Existing ShareholdersChongqing SharingContinue to invest further. The funds will mainly be used to advance the clinical trials of new drugs in the company's core pipeline, expand the technology platform, and strengthen the international strategic layout.

Zhou Yi, Head of Healthcare Investment at Shenzhen Capital GroupDeepVenture Capital has long been committed to investing in the healthcare and health industry, firmly optimistic about the cell therapy track. Autoimmune diseases are the second largest disease area after cancer, with significant unmet clinical needs and market potential. Universal cell therapy drugs have the potential to provide a new paradigm for the autoimmune disease field with controllable costs, long-term relief, and even cures. Since its establishment, Enrui Carano has rapidly iterated to build a proprietary underlying technology platform and a rich pipeline reserve. The team’s industry experience, high execution ability in project advancement, and excellent clinical data have won the favor of many investors. DeepVenture Capital will continue to leverage its "capital + post-investment empowerment" advantages to further support the company's R&D innovation in areas such as autoimmune diseases, accelerate global product layout, and benefit patients worldwide.

Zhao Liang, Deputy General Manager of Hengqin Venture CapitalHengqin Venture Capital focuses on early-stage science and technology innovation project investments, with long-term dedication to the healthcare sector, and continuous attention to the frontier of cell therapy. EndoCytix has demonstrated exceptional potential in the research and development of CAR-NK drugs and the innovation of underlying platform technologies. Hengqin Venture Capital will leverage its "pre-investment + post-investment empowerment" advantages to provide in-depth collaboration and resource support across multiple stages such as R&D, clinical trials, and industrialization, helping it grow into a biopharmaceutical company with global influence.

Luo Fei, Founding Partner of Pinehill CapitalRepresents: Pinehill Capital has long focused on the frontier of life sciences and has consistently been optimistic about the cell and gene therapy sector. Enrui Kanuo has established significant barriers in CAR-NK foundational technology and clinical translation, with its systemic lupus erythematosus pipeline at an internationally leading position. As co-lead investors, we will leverage Pinehill Capital's deep presence in the biopharmaceutical ecosystem to continuously empower Enrui Kanuo from multiple dimensions such as follow-up financing, talent acquisition, and industry resource alignment, supporting the company in accelerating its globalization process and bringing breakthrough therapies to patients as soon as possible.

Ji Haibin, Managing Partner of Tasly CapitalTasly Capital has long been firmly optimistic about cell therapy and has made extensive and in-depth investments. As one of the important branches of immune cell therapy, NK cell therapy is particularly promising for application in autoimmune diseases. Enrui Kailun is in the international first tier in the field of CAR-NK cell therapy for treating systemic lupus erythematosus, with clinical data already showing internationally leading efficacy and safety. We look forward to joining hands with Enrui Kailun to contribute more to the development of the cell therapy industry.

Tao Chunlei, Founder and Chairman of Anhui Wanbang PharmaceuticalAnhui Wanbang Pharmaceutical firmly believes in the cell therapy track and is honored to participate in Enruikainuo's current round of financing. We deeply appreciate Enruikainuo’s forward-looking layout, innovative courage, and pragmatic and efficient execution in the field of cell therapy. We look forward to working together with Enruikainuo in the future to jointly build an innovative drug development paradigm with global competitiveness.

Dr. Qian Hao, Co-founder and CEO of EncrinanoExpressed: Thanks to the recognition and support from investment institutions such as SDIC, Hengqin Venture Capital, Pinehurst Capital, Tasly Capital, and Anhui Wanbang Pharmaceutical! This round of financing is an affirmation of our scientific concepts and team capabilities, and will also provide a solid guarantee for the company's next stage of clinical research and platform expansion. We will adhere to the patient needs as the center, and continue to promote the research and implementation of innovative drugs.

The success of biopharmaceutical companies hinges on innovation at its core, with the key factors being pharmaceutical concepts and clinical pace. Over the past four years, Enrui Kainuo has built an innovative R&D team, an efficient CMC team, and a highly executable medical clinical and registration team.

Enrui Kainuo will further strengthen the innovation of core technologies, the upgrading of pipeline products, the expansion of clinical indications, and international cooperation, consolidating its leading position and cutting-edge exploration in the field of autoimmune diseases.

Shenzhen Rui Therapeutics Co., Ltd. was founded in 2021 as a platform company focused on the research and development of next-generation I&I drugs. Since its establishment, the team has been committed to innovating proprietary core technologies. Rui Therapeutics has built a leading CAR-NK technology platform in the I&I field and has also developed universalex vivoCAR-T and TCE multi-antibody platforms. The company focuses on inventive innovation, establishing core technologies with independent intellectual property rights, and has laid out the most cutting-edge First-in-class pipeline products, covering disease areas such as autoimmune diseases, inflammatory diseases, and fibrosis where clinical needs remain unmet.

Shenzhen Capital Group Co., Ltd. ("SCGC") was established in 1999 by the Shenzhen Municipal Government with the guidance of social capital investment. The company's mission is to discover and build great enterprises, committing to become an explorer and nurturer of innovative value. SCGC has developed into a comprehensive investment group focusing on venture capital. Its current registered capital is 10 billion yuan and manages various funds with a total scale of approximately 510 billion yuan. As of July 31, 2025, SCGC has invested in 2,038 venture projects (1,675 enterprises), of which 278 invested companies have been listed on 17 global capital markets (excluding the NEEQ).

Guangdong Hengqin Jintou Venture Capital Fund Management Co., Ltd. is an important investment platform under Zhuhai Technology Industry Group, focusing on the operation and management of mother funds and the incubation and cultivation of early-stage technology innovation projects. The company aligns with Zhuhai's emerging industries and future industrial layout, concentrating on subsectors such as next-generation information technology, pan-semiconductors, and healthcare. Adhering to the strategy of investing early, small, and innovative, it utilizes a "mother fund + direct investment" approach to accelerate Zhuhai's construction of a modern industrial system, foster new productive forces through venture capital aggregation, cultivate innovative projects, and attract high-end talent.

To date, the company's total scale of managed funds is approximately 14 billion yuan, with over 20 sub-funds invested cumulatively. It has invested in nearly 80 early-stage science and technology innovation projects, leveraging about 40 billion yuan of social capital. The company has introduced and nurtured tech star enterprises such as Aikangte, Yiwei Semiconductor, Molun New Materials, Zhen Health, Inming Biotechnology, and Mojie.

Songhe Capital was founded in 2007 (Songhe Venture Capital was established in 1996 as one of the earliest private venture capital institutions in Shenzhen and is the initiator of Songhe Capital). It was co-founded by venture capitalists Mr. Li Wei and Mr. Luo Fei, has weathered multiple economic cycles, operates steadily, and its core team has over 20 years of experience in equity investment. Songhe Capital focuses on early-stage and growth-stage investments, with key investments in three hard technology fields: digital technology, precision medicine, and innovative materials. To date, its asset management scale exceeds 18 billion yuan, with over 400 investment projects, assisting more than 60 outstanding companies in mergers and acquisitions or successful IPOs. Some of its portfolio companies include SenseTime (00020.HK), BGI Genomics (300676), Kintor Pharmaceuticals (09939.HK), Dynanonic (300769), MGI Tech (688114), and Orbbec (688322).

Tasly Capital has long been committed to carefully identifying the fundamental drivers of industry development. It focuses on "chokepoint" technologies at the frontiers of global science and technology, in the main economic battlefield, addressing major national needs, and improving people's health. The company seeks out high-quality projects that are non-replicable, irreplaceable, technologically mature, promising for industrial transformation, and have vast market potential. Relying on a professional, meticulous, and long-term dedicated fund management team, it continuously observes trends in structural reallocation within the industry. This allows the company to develop differentiated capabilities in predicting premium investment sectors, selecting foundational and key technologies, and identifying high-quality targets. In a complex, ever-changing yet opportunity-rich investment environment, Tasly Capital is committed to delivering predictable and sustainable returns for its investors.

Anhui Wanbang Pharmaceutical Technology Co., Ltd. (301520.SZ), as a leading domestic healthcare CRO, provides customers with one-stop services including pharmaceutical research, clinical research, data analysis, and registration applications. Its business covers multiple fields such as innovative drugs, generic drugs, medical devices, and health foods. The company has 18,000 square meters of R&D laboratories and over 80% of its staff are R&D personnel. With rich industry experience, a quality control system that meets international standards, and advanced equipment, the company has undertaken more than 1,300 projects to date, cumulatively testing over 2.3 million samples, receiving more than 500 acceptance numbers, and successfully obtaining approval for over 260 projects. Upholding the values of "simplicity, integrity, altruism, and innovation," Anhui Wanbang Pharmaceutical is committed to becoming a trusted and respected global CRO partner.